Imperial College London

Dr Mark P. Lythgoe

Faculty of MedicineDepartment of Surgery & Cancer

Clinical Research Fellow
 
 
 
//

Contact

 

m.lythgoe

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Summary

Dr Mark P. Lythgoe is an Academic Clinical Fellow in Medical Oncology and Pharmacist.  He is currently undertaking a PhD (primary supervisor Dr Jonathan Krell) exploring the cancer microbiome and live oral biotherapeutics as novel anti-cancer agents. Presently he oversees (principal investigator Dr Krell) the Imperial sponsored MICROBIOME trial (NCT03934827) with industry partner 4D Pharma exploring use of a live oral biotherapeutics (MRx0518) in patients with solid tumours awaiting surgical removal of the tumour. 

After studying Pharmacy at Aston University, Mark went on to graduate with a duel distinction in Medicine from Kings College London.  After completion of junior doctor posts in west London, he is now undertaking specialist academic training in Medical Oncology. He has also undertaken an academic clinical fellowship placement with Dr Rohini Sharma, exploring prognostic indices in high grade neuroendocrine tumours and PET imaging in a range of solid cancers, utilizing novel radionuclides to predict therapy responses. 

He has a range of academic interests including translational clinical trial development, cancer microbiome modulation as a therapeutic strategy, healthcare policy, improving clinical trial access and meta-research. He has also been a member of the Joint Formulary Committee for the British National Formulary (BNF) for 8 years.

He received an American Society of Cancer Merit Award in 2021 and has authored papers in the JAMA Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, and Trends in Pharmacological Sciences.  He also reviews manuscripts for several journals including Cancer, Scientific Reports, Trends in Pharmacological Sciences and European Journal of Cancer. 

Publications

Journals

Lythgoe MP, Sullivan R, 2022, Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval, European Journal of Cancer, Vol:169, ISSN:0959-8049, Pages:103-105

Benjamin DJ, Prasad V, Lythgoe MP, 2022, FDA decisions on new oncological drugs, The Lancet Oncology, Vol:23, ISSN:1470-2045, Pages:585-586

Lythgoe M, Krell J, 2022, Cancer therapy approval timings, review speed and publication of pivotal registration trials in the US and Europe from 2010-2019, Jama Network Open, ISSN:2574-3805

Talukder R, Makrakis D, Diamantopoulos LN, et al., 2022, Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin, Clinical Genitourinary Cancer, Vol:20, ISSN:1558-7673, Pages:165-175

Jenei K, Prasad V, Lythgoe MP, 2022, High US drug prices have global implications., Bmj, Vol:376

More Publications